Studies leading to the identification of ZD1839 (iressa™): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer Tập 11 Số 14 - Trang 1911-1914 - 2001
Andrew Barker, Keith H. Gibson, Walter Grundy, Andrew A. Godfrey, Jeffrey J Barlow, Mark P. Healy, J.R. Woodburn, Susan Ashton, Brenda J Curry, L. Scarlett, Lianne Henthorn, Laura M. Richards
The discovery of rofecoxib, [MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor Tập 9 Số 13 - Trang 1773-1778 - 1999
Petpiboon Prasit, Z Wang, Christine Brideau, Chi‐Chung Chan, S. Charleson, Wanda Cromlish, Diane Ethier, Jilly F. Evans, A W Ford‐Hutchinson, J. Y. GAUTHIER, Robert J. Gordon, Jocelyne Guay, Michael J. Gresser, Stacia Kargman, Brian P. Kennedy, Y. LEBLANC, Serge Léger, Joseph A. Mancini, Gary P. O’Neill, Marc Ouellet, M. David Percival, H. Perrier, Denis Riendeau, Ian W. Rodger, Philip Tagari, Michel Thérien, Philip J. Vickers, Elizabeth Wong, Li-Jing Xu, Robert N. Young, Robert Zamboni, S. Boyce, N.M.J. Rupniak, M J Forrest, Denise M. Visco, D Patrick
Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation Tập 23 Số 13 - Trang 3741-3748 - 2013
Pascal Furet, Vito Guagnano, Robin A. Fairhurst, Patricia Imbach‐Weese, Ian C. Bruce, Mark Knapp, Christine Fritsch, Francesca Blasco, Joachim Blanz, Reiner Aichholz, Jacques Hamon, Doriano Fabbro, Giorgio Caravatti
The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part 2: The second clinical candidate having a shorter and favorable human half-life Tập 20 Số 23 - Trang 7159-7163 - 2010
Jane L. Wang, David C. Limburg, Matthew J. Graneto, John R. Springer, Joseph Rogier Bruce Hamper, Subo Liao, Jennifer L. Pawlitz, Ravi G. Kurumbail, Timothy Maziasz, John J. Talley, James R. Kiefer, Jeffery Carter